Primary sources
What does my state say?
Pick your state for the pharmacy board, then read the federal baseline in clinic order: 503A lists, interim policy, PCAC, GLP-1 and Melanotan warnings, shortages, and DailyMed. Primary sources only.
Featured state guidance
High-traffic boards clinics ask about first. Full A–Z board index is below.
California
California Board of Pharmacy — Compounding
California’s compounding licensee page is the usual first stop for West Coast sterile programs and out-of-state pharmacy questions.
Texas
Texas volume means nonresident shipping and GLP-1 compounding questions show up early in most multi-state footprints.
Florida
Florida med-spa density makes office-use and nonresident pharmacy rules a frequent sales and compliance ask.
Ohio
Ohio has been visible on GLP-1 and med-spa enforcement topics; check current board communications before expanding menus.
Washington
Washington Pharmacy Quality Assurance Commission
Pacific Northwest sterile compounding posture; PQAC has issued semaglutide compounding communications.
New York
Dense Northeast market; outsourcing facility and nonresident pharmacy statutes set a high bar for office-use and interstate fills.
The federal baseline, in reading order
13 primary pages. The first four take about thirty minutes and cover most of what a pharmacy or counsel will ask.
- 1FDA Human Drug Compounding Overview
Defines the federal compounding frame clinics and pharmacies argue inside.
- 2FDA Section 503A Bulk Drug Substances Lists
The starting map for whether a bulk peptide can even be nominated or listed for patient-specific compounding.
- 3FDA 503A Category 1 / 2 / 3 bulk substances list (PDF)
The downloadable category list clinics and pharmacies argue from when someone claims a bulk peptide is “on the list.”
- 4Bulk substances that may present significant safety risks
Names substances FDA associates with compounding safety concerns. Read the current page before building a menu.
- 5Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (PDF)
Defines Category 1 enforcement discretion and what sits outside the interim policy after the January 2025 revision.
- 6FDA 503A bulk drug substance pathways (interim policy)
Explains statutory pathways and interim Category 1 posture after the Jan 2025 policy revision.
- 7July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting
Meeting page and materials for the 2026 peptide votes. Advisory recommendations are not final FDA decisions.
- 8FDA concerns with unapproved GLP-1 drugs used for weight loss
Explains why compounded GLP-1 programs need tighter intake and syringe counseling.
- 9FDA Drug Shortages Database
Shortage status changes what compounding pathways pharmacies will defend.
- 10FDA Unapproved Drugs Initiative
Context for enforcement against products marketed for human use without approval.
- 11FDA warning on unapproved and potentially dangerous tanning products
Primary citation when clinics ask whether Melanotan II belongs anywhere near a menu.
- 12FDA information on outsourcing facilities (503B)
Baseline for office-use and larger-batch compounding outside patient-specific 503A.
- 13DailyMed labeled drug information
Fast check that a “branded” peptide ask actually has a labeled finished drug (Wegovy, Forzinity, Scenesse, Victoza).
Indexes and supervision
NABP
NABP State Board of Pharmacy Links
Master index when a board URL drifts or your footprint leaves this catalog.
FSMB
Federation of State Medical Boards
Starting point for medical-board supervision questions that pharmacy boards do not answer.
All 51 pharmacy boards, A to Z
Expand
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Sources in hand? See how clinics run the program.
Once counsel and your pharmacy agree on the menu, the PeptIQ.io provider console handles the rest: protocol templates, patient logging between visits, adherence per patient, and refill nudges.
Educational reference only, not legal, medical, or regulatory advice. PeptIQ.io does not sell, source, or dispense peptides. Your counsel, your pharmacy, and your state boards decide what applies to your clinic. Verify every source before you rely on it.